Are Wall Street Analysts Predicting Quest Diagnostics Stock Will Climb or Sink?
/Quest%20Diagnostics%2C%20Inc_%20logo%20on%20building-by%20Tada%20Images%20via%20Shutterstock.jpg)
Quest Diagnostics Incorporated (DGX), headquartered in Secaucus, New Jersey, offers diagnostic testing and services globally. Valued at $20 billion by market cap, the company operates a national network of full-service laboratories, rapid-response laboratories, and patient service centers. DGX offers esoteric, routine medical, drugs of abuse, and non-hospital-based anatomic pathology testing services.
Shares of this leading diagnostic testing & services provider have outperformed the broader market over the past year. DGX has gained 16.4% over this time frame, while the broader S&P 500 Index ($SPX) has rallied nearly 14.3%. In 2025, DGX stock is up 18.4%, surpassing SPX’s 9.5% rise on a YTD basis.
Zooming in further, DGX’s outperformance is also apparent compared to SPDR S&P Health Care Services ETF (XHS). The exchange-traded fund has declined about 1.4% over the past year. Moreover, DGX’s double-digit returns on a YTD basis outshine the ETF’s 8.1% gains over the same time frame.
On Jul. 22, DGX shares closed up more than 7% after reporting its Q2 results. Its adjusted EPS of $2.62 topped Wall Street expectations of $2.57. The company’s revenue was $2.8 billion, beating Wall Street forecasts of $2.7 billion. DGX expects full-year adjusted EPS in the range of $9.63 to $9.83, and expects revenue in the range of $10.8 billion to $10.9 billion.
For the current fiscal year, ending in December, analysts expect DGX’s EPS to grow 9.1% to $9.74 on a diluted basis. The company’s earnings surprise history is impressive. It beat the consensus estimate in each of the last four quarters.
Among the 18 analysts covering DGX stock, the consensus is a “Moderate Buy.” That’s based on nine “Strong Buy” ratings, and nine “Holds.”
This configuration is less bullish than a month ago, with nine analysts suggesting a “Strong Buy.”
On Aug. 25, Baird downgraded DGX to a “Neutral” rating with a price target of $194, implying a potential upside of 8.6% from current levels.
The mean price target of $188.71 represents a 5.6% premium to DGX’s current price levels. The Street-high price target of $200 suggests an upside potential of 11.9%.
On the date of publication, Neha Panjwani did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.